These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 28697344)

  • 1. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.
    Shukla SK; Purohit V; Mehla K; Gunda V; Chaika NV; Vernucci E; King RJ; Abrego J; Goode GD; Dasgupta A; Illies AL; Gebregiworgis T; Dai B; Augustine JJ; Murthy D; Attri KS; Mashadova O; Grandgenett PM; Powers R; Ly QP; Lazenby AJ; Grem JL; Yu F; Matés JM; Asara JM; Kim JW; Hankins JH; Weekes C; Hollingsworth MA; Serkova NJ; Sasson AR; Fleming JB; Oliveto JM; Lyssiotis CA; Cantley LC; Berim L; Singh PK
    Cancer Cell; 2017 Jul; 32(1):71-87.e7. PubMed ID: 28697344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia-mediated attenuation of EGLN2 inhibition of the NF-κB signaling pathway leads to the formation of a loop between HIF-1α and MUC1-C promoting chemoresistance in bladder cancer.
    Qing L; Li Q; Yang Y; Xu W; Wang Y; Li R; You C; Dong Z
    Mol Carcinog; 2024 Jul; 63(7):1303-1318. PubMed ID: 38634741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stem cell factor modulates HIF-1α levels and diminishes 5-FU sensitivity in 5-FU resistant pancreatic cells by altering the anabolic glucose metabolism.
    Xiang F; Luo F
    J Biochem Mol Toxicol; 2023 Dec; 37(12):e23487. PubMed ID: 37718545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer.
    Chaika NV; Gebregiworgis T; Lewallen ME; Purohit V; Radhakrishnan P; Liu X; Zhang B; Mehla K; Brown RB; Caffrey T; Yu F; Johnson KR; Powers R; Hollingsworth MA; Singh PK
    Proc Natl Acad Sci U S A; 2012 Aug; 109(34):13787-92. PubMed ID: 22869720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1α in pancreatic cancer cells.
    Wang R; Cheng L; Xia J; Wang Z; Wu Q; Wang Z
    Curr Cancer Drug Targets; 2014; 14(4):407-17. PubMed ID: 24575976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-37/ STAT3/ HIF-1α negative feedback signaling drives gemcitabine resistance in pancreatic cancer.
    Zhao T; Jin F; Xiao D; Wang H; Huang C; Wang X; Gao S; Liu J; Yang S; Hao J
    Theranostics; 2020; 10(9):4088-4100. PubMed ID: 32226541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PVT1 Knockdown Inhibits Autophagy and Improves Gemcitabine Sensitivity by Regulating the MiR-143/HIF-1α/VMP1 Axis in Pancreatic Cancer.
    Liu YF; Luo D; Li X; Li ZQ; Yu X; Zhu HW
    Pancreas; 2021 Feb; 50(2):227-234. PubMed ID: 33565800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κB- and hypoxia-inducible factor 1α-mediated up-regulation of CXCR4.
    Arora S; Bhardwaj A; Singh S; Srivastava SK; McClellan S; Nirodi CS; Piazza GA; Grizzle WE; Owen LB; Singh AP
    J Biol Chem; 2013 Jul; 288(29):21197-21207. PubMed ID: 23740244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia-inducible factor-1α expression and gemcitabine chemotherapy for pancreatic cancer.
    Kasuya K; Tsuchida A; Nagakawa Y; Suzuki M; Abe Y; Itoi T; Serizawa H; Nagao T; Shimazu M; Aoki T
    Oncol Rep; 2011 Dec; 26(6):1399-406. PubMed ID: 21922147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIF-1α-regulated stanniocalcin-1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signaling pathway.
    Zhao F; Yang G; Qiu J; Liu Y; Tao J; Chen G; Su D; You L; Zheng L; Zhang T; Zhao Y
    Mol Carcinog; 2022 Sep; 61(9):839-850. PubMed ID: 35785493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDH2 stabilizes HIF-1α-induced metabolic reprogramming and promotes chemoresistance in urothelial cancer.
    Shigeta K; Hasegawa M; Hishiki T; Naito Y; Baba Y; Mikami S; Matsumoto K; Mizuno R; Miyajima A; Kikuchi E; Saya H; Kosaka T; Oya M
    EMBO J; 2023 Feb; 42(4):e110620. PubMed ID: 36637036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The MUC1-HIF-1α signaling axis regulates pancreatic cancer pathogenesis through polyamine metabolism remodeling.
    Murthy D; Attri KS; Suresh V; Rajacharya GH; Valenzuela CA; Thakur R; Zhao J; Shukla SK; Chaika NV; LaBreck D; Rao CV; Hollingsworth MA; Mehla K; Singh PK
    Proc Natl Acad Sci U S A; 2024 Apr; 121(14):e2315509121. PubMed ID: 38547055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia regulates ABCG2 activity through the activivation of ERK1/2/HIF-1α and contributes to chemoresistance in pancreatic cancer cells.
    He X; Wang J; Wei W; Shi M; Xin B; Zhang T; Shen X
    Cancer Biol Ther; 2016; 17(2):188-98. PubMed ID: 26785721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quercetin potentializes the respective cytotoxic activity of gemcitabine or doxorubicin on 3D culture of AsPC-1 or HepG2 cells, through the inhibition of HIF-1α and MDR1.
    Hassan S; Peluso J; Chalhoub S; Idoux Gillet Y; Benkirane-Jessel N; Rochel N; Fuhrmann G; Ubeaud-Sequier G
    PLoS One; 2020; 15(10):e0240676. PubMed ID: 33052979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.
    Zhao T; Ren H; Jia L; Chen J; Xin W; Yan F; Li J; Wang X; Gao S; Qian D; Huang C; Hao J
    Oncotarget; 2015 Feb; 6(4):2250-62. PubMed ID: 25544770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AGR2-induced glucose metabolism facilitated the progression of endometrial carcinoma via enhancing the MUC1/HIF-1α pathway.
    Gong W; Ekmu B; Wang X; Lu Y; Wan L
    Hum Cell; 2020 Jul; 33(3):790-800. PubMed ID: 32304027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycolysis addiction compensating for a defective pentose phosphate pathway confers gemcitabine sensitivity in SETD2-deficient pancreatic cancer.
    Shen X; Chen Y; Liu M; Shi J; Tang Y; Yang X; Xu D; Yao H; Lu P; Sun Y; Xue J; Niu N
    Biochem Biophys Res Commun; 2022 Jul; 615():9-16. PubMed ID: 35679751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer.
    Halbrook CJ; Pontious C; Kovalenko I; Lapienyte L; Dreyer S; Lee HJ; Thurston G; Zhang Y; Lazarus J; Sajjakulnukit P; Hong HS; Kremer DM; Nelson BS; Kemp S; Zhang L; Chang D; Biankin A; Shi J; Frankel TL; Crawford HC; Morton JP; Pasca di Magliano M; Lyssiotis CA
    Cell Metab; 2019 Jun; 29(6):1390-1399.e6. PubMed ID: 30827862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIF-1-dependent heme synthesis promotes gemcitabine resistance in human non-small cell lung cancers via enhanced ABCB6 expression.
    Xiang L; Wang Y; Lan J; Na F; Wu S; Gong Y; Du H; Shao B; Xie G
    Cell Mol Life Sci; 2022 Jun; 79(6):343. PubMed ID: 35661930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.